Scientific Programme Sunday, 12 June 2016 16:00

Transcription

Scientific Programme
Sunday, 12 June 2016
Plenary Session, 517 D
16:00 - 17:30
PL1
Opening Lecture
Chair: John Rioux (Université de Montréal & Montreal Heart Institute, Montreal,
Canada)
16:00 - 16:30
Activating the Right of Citizens to Benefit from Scientific Advances
Bartha Maria Knoppers (McGill University, Montreal, Canada)
16:30 - 17:30
Discovering and Developing Precision Medicines
David Altshuler (Vertex, United States)
Special Events, Terrasse 720
17:30 - 19:30
Page 1 / 19
Welcome Reception
Monday, 13 June 2016
Industry Symposium, 517 D
07:00 - 07:45
IS1
07:00 - 07:45
Symposium Novartis
Cancer immunotherapy and regenerative medicine: Paradigm of
Personnalized Medicine
Denis Claude Roy (Hôpital Maisonneuve-Rosemont, University of Montreal,
Montreal, Canada)
08:00 - 09:30
PL1
Opening Ceremony and Plenary
Welcome address from dignitaries:
- Dr Pavel Hamet, Congress president
- David Bouthillier, Quebec Network for Personalized Health Care
- Dre Johanne Tremblay, Scientific Committee Chair
Chair: Pavel Hamet (CHUM, Montreal, Canada)
08:00 - 08:45
Welcome address from dignitaries
08:45 - 09:30
Opportunities and Challenges in the Implementation of Precision
Medicine
Victor Dzau (National Academy of Medicine, United States)
Poster Session, 517 BC Exhibit Hall
Poster Session
For details on presentations and authors, please refer to Poster session on Tuesday, June 14, at 18h00
Coffee breaks, 517 BC Exhibit Hall
09:30 - 10:00
Coffee Break
Session, 524 ABC
10:00 - 12:00
CS1
Personalized Medicine and Common Diseases
Chair: Johanne Tremblay (University of Montreal, Canada)
Page 2 / 19
10:00 - 10:30
Next Generation Sequencing in Diabetes for Theranostics and
Personalized Medicine
Philippe Froguel (Imperial College London, London, United Kingdom)
10:30 - 10:45
Impact of Personalized Treatment Optimization Service in a Community
Pharmacy for Patients with Chronic Diseases
Peter Tolios (University of Toronto, Toronto, Canada)
10:45 - 11:00
Validation of Caucasian Genetic Determinants of Unmet Needs in the
Treatment of Kidney Disease in Type-2 Diabetes
Paul Simon (McGill University, Montreal, Canada)
11:00 - 11:15
Integrating Genomic and Environmental Features to Map Critical Factors
in Individual Development of Chronic Diseases
Marie-Julie Favé (Université de Montréal, Montreal, Canada)
11:15 - 11:30
A Personalized Approach for Assessing Pancreatic Function in Diabetes
Using Novel Islet Biomarkers
Eustache Paramithiotis (Caprion Biosciences, Montreal, Canada)
Session, 519 AB
10:00 - 12:00
CS2
Personalized Medicine and Rare/Orphan Diseases
Chair: Étienne Richer (CIHR Institute of Genetics, Montreal, Canada)
10:00 - 10:15
Treatment of Hereditary Diseases with the CRISPR/Cas9 Technology
Jacques P. Tremblay (Université Laval, Quebec, Canada)
10:15 - 10:30
Unraveling the Coding and Non-Coding Basis of Rare Disease: New
Approaches for Genetic Risk Assessment of Congenital Heart Disease
Christoph Preuss (Centre Hospitalier Universitaire Sainte-Justine Research Centre,
Université de Montréal, Montréal, Canada)
10:30 - 10:45
Epigenetic Regulation by Pro-Inflammatory Transcription Factors: A
Toolbox for Candidate Gene Identification in GWAS Loci
David Langlais (McGill University, Montreal, Canada)
10:45 - 11:00
Discovery and Impact of Treatable Rare Genetic Diseases in
Schizophrenia and Bipolar Disorder Populations
Venuja Sriretnakumar (University of Toronto, Toronto, Canada)
11:00 - 11:15
Antibody-Proteases as a Novel Biomarker and thus a Target to Monitor
and to Prevent Demyelination
Sergey Suchkov (I.M.Sechenov First Moscow State Medical University, Moscow,
Russian Federation)
11:15 - 11:30
A Variant Allele of Growth factor independence 1 (GFI136N) as a
Biomarker, Risk Factor and New Target for Rare Myeloid Neoplasia
Tarik Möröy (Institut de recherches cliniques de Montreal, Montreal, Canada)
11:30 - 12:00
Lessons from Plans and Strategies for Rare Diseases in Europe
Segolene Ayme (INSERM, Paris, France)
Page 3 / 19
Panel, Innovation Zone 517BC
10:00 - 11:30
Comment rendre la médecine personnalisée accessible aux
pays à moindre revenus : l'Afrique sub-saharienne
(session présentée en français / session presented in
French)
Ce panel vise à entamer des discussion sur le thème de la médecine de
précision/personnalisée qui devient rapidement le « gold standard » des nouvelles
pratiques de la médecine. Le sous-thème est l’accessibilité des ces nouvelles
pratiques aux pays émergents.
Cette session sera présentée en français.
Chair: Yves Tremblay (AIICM, Québec, Canada)
10:00 - 11:30
Comment rendre la médecine personnalisée accessible aux pays à
moindre revenus : l'Afrique sub-saharienne
Étienne Lemarie (Université François-Rabelais, Tours, France)
Pavel Hamet (CHUM, Montreal, Canada)
Candan Hızel (Pharmacogenomics Research Centre-BIFAGEM, Izmir, Turkey)
Abdel Karim Koumaré (Faculté de Médecine de Pharmacie et
d'Odontostomatologie (FMPOS), Bamako, Mali)
Anne Marie Antchouey Ambourhouet (Ministère de la santé, Gouvernement du
Gabon, Libreville, Gabon)
Marie Hatem (Université de Montréal, École de Santé Publique, Montreal, Canada)
12:00 - 13:00
IS2
12:00 - 12:45
Symposium Pfizer
Precision Cardiovascular Medicine
Jean-Claude Tardif (Montreal Heart Institute, Canada)
Small Meeting, Salle de réunion 518 B
12:00 - 17:00
P5
Les besoins et défis des soins santé personnalisés en
Afrique
Chair: Yves Tremblay (AIICM, Québec, Canada)
Chair: Étienne Lemarie (Université François-Rabelais, Tours, France)
Session, 524 ABC
13:15 - 14:45
CS3
Genetics Related Ethical, Environmental, Economic, Legal
and Social Issues (GE3LS)
Chair: Ma'n Zawati (Centre of Genomics and Policy – McGill University, Montreal,
Canada)
Page 4 / 19
13:15 - 13:45
Are Data Sharing and Privacy Protection Mutually Exclusive in
Personalized Health Research?
Yann Joly (McGill University, Montreal, Canada)
13:45 - 14:00
The GE3LS that Bind: Moving forward with the Precision Medicine Policy
Network
François Rousseau (Université Laval, Québec, Canada)
14:00 - 14:15
Identifying and Communicating Risks in Gene Environment Interaction
Research: Thought-leader Perspectives on Informed Consent
Catherine M. Hammack (Duke Clinical Research Institute, Durham, United States)
14:15 - 14:30
Biochemical and Epistemic Heterogeneity in Rare Disease Treatment
Debates: An Anthropological Perspective
Marlee McGuire (University of British Columbia, Vancouver, Canada)
14:30 - 14:45
P3G DataTrust – Developing a DataTrust Service for Personalized
Medicine Research
Emily Kirby (Public Population Project in Genomics and Society (P3G), Montréal,
Canada)
Session, 519 AB
13:15 - 15:00
LSARP1
From Screening to Therapies (presented by Genome
Canada and CIHR)
Chair: Dan Roden (Vanderbilt University Medical Center, Nashville, United States)
13:15 - 13:35
PACE - 'Omics: Personalized, Accessible, Cost-Effective applications of
'Omics technologies
Christopher McCabe (University of Alberta, Canada)
13:35 - 13:55
Enhanced CARE for RARE Genetic Diseases in Canada
Kym Boycott (CHEO Research Institute, Ottawa, Canada)
13:55 - 14:15
The ICHANGE (International CHildhood Astrocytomas iNtegrated
Genomics and Epigenomics) Consortium
Jacek Majewski (McGill University, Montreal, Canada)
14:15 - 14:35
Translating Genetic Discoveries into a Personalized Approach to Treating
the Inflammatory Bowel Diseases
John Rioux (Université de Montréal & Montreal Heart Institute, Montreal, Canada)
14:35 - 14:55
Vancouver Island: An Omics Testbed - Changing the Care of Stroke
Andrew Penn (Island Health, Victoria, Canada)
14:45 - 15:15
Page 5 / 19
Coffee Break
Panel, 524 ABC
15:15 - 16:45
P2
Implementation of Personalized Health Care: Regulatory
Challenges and Policy Options
Chair: Yann Joly (McGill University, Montreal, Canada)
15:15 - 16:45
Implementation of Personalized Health Care: Regulatory Challenges and
Policy Options
Lawrence J. Lesko (University of Florida College of Pharmacy, Orlando, United
States)
Michèle de Guise (INESSS, Montreal, Canada)
Patrice Sarrazin (Health Canada, Ottawa, Canada)
Angela Brand (Maastricht University, Maastricht, Netherlands)
Session, 519 AB
15:15 - 16:45
CS5
Implication of Professionals and Patients in Personalized
Health Care
Chair: Kym Boycott (CHEO Research Institute, Ottawa, Canada)
15:15 - 15:45
Preparing Primary Care Providers for Personalized Genomic Medicine:
Challenges and Successes
June Carroll (University of Toronto, Toronto, Canada)
15:45 - 16:00
Expectations of Hospital Pharmacists and Pharmacy Residents from
Quebec towards Pharmacogenomics
Denis Lebel (Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada)
16:00 - 16:15
Personalizing Health Care: The Genomics ADvISER - A Genomics Decision
AiD about Incidental SEquencing Results
Yvonne Bombard (University of Toronto, Li Ka Shing Knowledge Institute of St.
Michael's Hospital, Toronto, Canada)
16:15 - 16:30
The Added Value of Clinical Laboratories in Personalized Medicine: The
Evidence
Edgard Delvin (CHU Ste-Justine Research Centre, Montreal, Canada)
16:30 - 16:45
La Banque Signature, un modèle de recherche clinique pour le futur de la
recherche en santé mentale
Nathe François (Centre de recherche de l'IUSMM du CIUSSS de l'Est-de-l'Île-deMontréal, Montréal, Canada)
17:00 - 18:00
PL2
Global Genomic Knowledge: Local Precision Medicine
Chair: Nathalie Ouimet (Montreal InVivo, Montreal, Canada)
17:00 - 18:00
Global Genomic Knowledge: Local Precision Medicine
Peter Goodhand (Global Alliance for Genomics and Health, Toronto, Canada)
Page 6 / 19
Special Events, Innovation Zone 517BC
18:00 - 20:00
Carrefour santé personnalisée (conférence publique)
Le Carrefour santé personnalisée est une activité gratuite qui vise à informer le
grand public des développements en médecine personnalisée et des impacts de
cette médecine de demain sur la vie et la santé des Québécois.
Le journaliste, animateur et producteur primé Stéphan Bureau
assurera l’animation de la soirée.
Au programme:
- Qu’est-ce que la médecine personnalisée ?
Une entrevue animée avec David Levine, administrateur d’établissements de
santé et président du Regroupement en soins de santé personnalisés au Québec,
viendra démystifier ce qu’est la médecine personnalisée.
- Cancer du sein et médecine personnalisée : je m’informe !
Présenté en collaboration avec la Fondation du cancer du sein du Québec, ce
panel de discussion permettra de mieux comprendre les notions de risques et de
prévention en cancer du sein qu’offre la médecine personnalisée. Cette discussion
accueillera deux spécialistes à la fine pointe des questions sur le risque et sur la
prévention ainsi qu’une survivante du cancer du sein qui partagera son expérience
:
• Dr Jacques Simard, professeur et détenteur de la Chaire de recherche du Canada
en oncogénétique, Faculté de médecine Université Laval
• Dre Jocelyne Chiquette, omnipraticienne et directrice médicale du Centre R.O.S.E
de l’hôpital du St-Sacrement
• Maude Schiltz, survivante d’un cancer du sein et auteure du livre Ah shit, j’ai
pogné le cancer
- Soins de santé personnalisés : Quel rôle pour le patient et le médecin ?
Ce deuxième panel abordera les considérations légales, cliniques et éthiques liées
à la divulgation des résultats médicaux : Comment devrait se faire la divulgation
des résultats ? Qui devrait le faire ? Quelles sont les implications familiales ?
Comment accueillir les résultats du point de vue du patient ? Afin de nous éclairer,
les experts suivants se pencheront sur ces questions :
• Dr Pavel Hamet, professeur de médecine, Chaire de recherche du Canada,
Génomique prévisionnelle
• Me Ma’n Zawati, directeur général Centre de génomique et politiques, Université
McGill
• Laurence Baret, conseillère en génétique Centre universitaire de santé McGill
• Marjolaine Verville, co-fondatrice de la Fondation sur les leucodystrophies et
mère du jeune Alexis atteint d'une leucodystrophie
Page 7 / 19
Tuesday, 14 June 2016
07:15 - 08:15
IS3
07:15 - 08:15
Symposium Merck
Perspectives on Personalized Cancer Care – They Are Personal Too
Paul Wheatley Price (University of Ottawa, Ottawa, Canada)
08:30 - 09:30
PL3
Tools for Personalizing Medicine from Patients to
Populations
Chair: Daniel Bouthillier (Quebec Network for Personalized Health Care, Montreal,
Canada)
08:30 - 09:30
Tools for Personalizing Medicine from Patients to Populations Big Data
and Little Data in an Era of Personalized Healthcare
Dan Roden (Vanderbilt University Medical Center, Nashville, United States)
Poster Session
For details on presentations and authors, please refer to Poster session at 18h00
09:30 - 10:00
Coffee Break
Session, 524 ABC
10:00 - 11:50
CS6
Biomarkers for Detection, Prevention and Prognosis
Chair: Pavel Hamet (CHUM, Montreal, Canada)
10:00 - 10:30
Personalised Cancer Screening and Prevention Programmes: Are We
There Yet?
Nora Pashayan (University College London, London, United Kingdom)
10:30 - 11:00
Biomarkers for Cancer Care
Raju Kucherlapati (Harvard Medical School, Boston, United States)
11:00 - 11:20
A Highly Informative Biomarker Strategy for Complex Neurodegenerative
Diseases using Structural Variations
Allen Roses (Cabernet Pharmaceuticals, Inc, Chapel Hill, United States)
Page 8 / 19
11:20 - 11:35
Quantifying Signaling Pathway Activity by iMALDI
Mark Basik (McGill University, Montreal, Canada)
11:35 - 11:50
Pertinence d’une analyse multigène élargie dans l’évaluation génétique
des cancers du sein et l’ovaire. Impact sur la personnalisation des soins
Zaki El Haffaf (Univerrsité de Montréal, Montreal, Canada)
Session, 519 AB
10:00 - 11:45
CS7
Quebec’s Public-private Partnerships Les soins de santé
personnalisés au Québec, la réussite du modèle de
partenariats public-privé (presented by Ministère de
l'Économie, de la Science et de l'Innovation - MESI)
Chair: Patrick Tremblay (Caprion BioSciences Inc, Montreal, Canada)
10:00 - 10:10
Quebec’s Public-private Partnerships « Les partenariats publics-privés,
l’expérience Québécoise”
Marco Blouin (Ministère de l’Économie, de la Science et de l’Innovation, Montréal,
Canada)
10:10 - 10:20
The Progress on the Promise of Delivering Personalized Medicine for
Cancer in Quebec: A presentation on Quebec’s partnership for
Personalized Medicine Partnership for Cancer
Martin Leblanc (Caprion BioSciences Inc, Montréal, Canada)
10:20 - 10:35
Presentation of a report conducted for the Personalized Medicine
Partnership for Cancer (PMPC): Diagnostic Test Reimbursement
Mélanie Bourassa-Fortier (University of Sherbrooke, Sherbrooke, Canada)
10:35 - 10:50
Presentation of a Report for the PMPC: Evaluation of a Real-life Situation
Jean Lachaine (Université de Montréal, Montreal, Canada)
10:50 - 11:00
Partnership Fund for an Innovative and Healthy Québec (PFIHQ): a
Preliminary Assessment
Vanessa Claveau (MESI, Montreal, Canada)
11:00 - 11:15
Q-CROC: Creating a Better Clinical Research Ecosystem
Martin Gagnon (Q-CROC (Clinical Research Organization in Cancer), Montreal,
Canada)
11:15 - 11:45
Panel - The key success factors in Quebec’s public-private health
partnership model and collaborative opportunities in health research and
innovation between industrial and public research centers
Marie-Pierre Dubé (Beaulieu-Saucier Pharmacogenomics Center, Montreal,
Canada)
Daniel Bouthillier (Quebec Network for Personalized Health Care, Montreal,
Canada)
Page 9 / 19
12:00 - 13:00
IS4
12:00 - 12:45
Symposium Roche
Three Cancer Patients, The Same Mutation, Three Different Journeys
Tom Grogan (Ventana Medical Systems, Inc. / Roche Tissue Diagnostics, Tucson,
United States)
Panel, 517 D
13:15 - 14:45
P1
Le rôle des administrateurs dans la personnalisation des
soins (table ronde présentée en français) (Panel
presented in French)
L’innovation en santé, combinée à la meilleure connaissance des besoins des
patients et à la découverte de traitements mieux ciblés selon le profil génétique,
transforme notre système de santé. En pleine ébullition, celui-ci se veut innovant
et apprenant, en étant fondé sur la collaboration entre patients, cliniciens,
gestionnaires. L’approche des soins personnalisés, de plus en plus présente dans
le milieu de la santé, permet de combiner le savoir, l’expertise et le travail
interdisciplinaire des professionnels au bénéfice du patient et de ses proches.
Chair: Fabrice Brunet (CHUM, Montréal, Canada)
Les besoins de la population exprimés
Anne Robert (Montreal, Canada)
L'utilisation des bases de données pour s'assurer de la pertinence des
interventions
Les soins personnalisés dans la restructuration du système de santé du
Québec
Luc Castonguay (Ministère de la Santé et des Services sociaux, Québec, Canada)
Le rôle de l'infirmière praticienne spécialisée (IPS) dans les soins
personnalisés de première ligne
Francine Ducharme (Université de Montréal, Montreal, Canada)
Session, 524 ABC
13:15 - 14:45
13:15 - 13:45
CS4
Cloud Computing / Big Data
Big and Fat Data in Life Sciences
François Laviolette (Big Data Research Centre (BDRC) Université Laval, Québec,
Canada)
13:45 - 14:15
The 100,000 Genomes Project, UK
Tom Fowler (Genomics England, London, United Kingdom)
14:15 - 14:35
A New World of Biobanking: CARTaGENE, Created to Accelerate Research
and Breakthroughs in Personalized Medicine
Joseph Tcherkezian (CHU Ste-Justine Research Centre-CARTaGENE, Montréal,
Canada)
Page 10 / 19
Session, 519 AB
13:15 - 14:45
LSARP2
"Low Hanging Fruit" of Oncology (presented by Genome
Canada and CIHR)
Chair: Raju Kucherlapati (Harvard Medical School, Boston, United States)
13:15 - 13:35
Personalised Risk Stratification for Prevention and Early Detection of
Breast Cancer
Jacques Simard (Genomics Center, CHU de Québec - Université Laval Research
Center, Québec, Canada)
13:35 - 13:55
Personalized Treatment of Lymphoid Cancer: BC as a Model Province
Joseph Connors (BC Cancer Agency Centre for Lymphoid Cancer, Vancouver,
Canada)
13:55 - 14:15
Personalized Cancer Immunotherapy
Montreal, Canada)
14:45 - 15:15
Coffee Break
Session, 524 ABC
15:15 - 16:45
CS8
Economic Impact and Outcome Research
Chair: Jacques Simard (Genomics Center, CHU de Québec - Université Laval
Research Center, Québec, Canada)
15:15 - 15:45
Generating Economic Evidence to Support Personalized Health Care
Katherine Payne (The University of Manchester, Manchester, United Kingdom)
15:45 - 16:00
A Global Economic Model to Evaluate the Cost-Effectiveness of Targeted
Treatments Using Companion Diagnostics in Advanced/Metastatic Cancer
Treatment
Jean Lachaine (Université de Montréal, Montreal, Canada)
16:00 - 16:15
Evaluation and Validation of a Personalized Patient Reported Outcome
Technique - PMO Approach
Sravan Jaggumantri (University of British Columbia, Vancouver, Canada)
16:15 - 16:30
Noninvasive Prenatal Screening for Common Aneuploidies in a Canadian
Province: A Cost Effectiveness Analysis
Léon Nshimyumukiza (Laval University, Québec, Canada)
16:30 - 16:45
Clinical Activity Prompted by Pediatric Whole Genome Sequencing
Compared to Chromosome Microarray
Robin Hayeems (Hospital for Sick Children, Toronto, Canada)
Page 11 / 19
Session, 519 AB
15:15 - 17:00
CS9
Challenges in Implementation of Personalized Medicine
Chair: Philippe Froguel (Imperial College London, London, United Kingdom)
15:15 - 15:45
Omic Biosignatures - From Unmet Needs to Clinical Impact
Bruce McManus (PROOF Centre of Excellence, Vancouver, Canada)
15:45 - 16:00
Great Expectations: Challenges of Developing and Commercializing
Diagnostics in the Era of Personalized Medicine
Patrick Tremblay (Caprion BioSciences Inc, Montreal, Canada)
16:00 - 16:15
Challenges in Obtaining and Enforcing Personalized Medicine Patents in
the United States
Marsha Rose Gillentine (Sterne, Kessler, Goldstein & Fox P.L.L.C., Washington,
United States)
16:15 - 16:30
Infusion of Personalized Donor Lymphocytes Depleted of Alloreactive TCells (ATIR101) Improves Overall Survival and Reduces Transplant
Related Mortality after T-Cell Depleted Haploidentical Stem Cell
Transplantation
Montreal, Canada)
16:30 - 16:45
Patent Protection in Molecular Diagnostics: Stakeholder Positions and
Expected Impacts
Katherine Bonter (PCITP, Hopital Maisoneuve Rosemont, Montreal, Canada)
16:45 - 17:00
Whole-Exome Sequencing in the Clinic: Where are we in Québec and
France?
Gabrielle Bertier (McGill University, Montréal, Canada)
Session, Innovation Zone 517BC
15:15 - 16:45
CS10
Leveraging Moleculars LIMS to Deliver Precision Medicine Newborn Screening Ontario Report
Learning Objectives:
1. Differences between conventional LIS and MDx lab software
2. Laboratory operational benefits to deploying MDx software – Patient safelty via
accurate samplle tracking (example protracted NGS analysis) Turnaround time
(TAT), efficiency, quality, audit success etc.
3. Business benefits to deploying MDx software –
a. client service – prompt, comprehensive and comprehensible reporting
b. capability to capture new opportunities (in Canada Test Repatriation?)
c. capability to respond to business challenges (in US changing reimbursement as
an example).
c. enhanced preparedness and responsiveness to emergent public health threats
4. Cloud based compared to institutional infrastructure considerations
5. Deployment for bi-lingual or multi-lingual environments – what are the options.
6. Adapting to new innovations in “omic” science – Pharmacogenomics, Next
Generation Sequencing, Whole Genome Sequencing, CRISPR, and beyond?
Chair: Richard Mandahl (UNICONNECT, Salt Lake CIty, United States)
Page 12 / 19
15:15 - 15:25
Leveraging Moleculars LIMS to Deliver Precision Medicine - Newborn
Screening Ontario Report
Lemuel J. Racacho (Children's Hospital of Eastern Ontario, - Newborn Screening
Ontario, Ottawa, Canada)
Steve Conrad (Newborn Screening Ontario, Ottawa, Canada)
Jordan Lerner-Ellis (Mt Sinai Hospital, Toronto, Canada)
17:00 - 18:00
PL4
Implementation of Personalized Health Care Worldwide
Chair: Michelle Savoie (Université de Montréal, Canada)
17:00 - 17:10
Personalized Medicine: The Changing Landscape of Health Care
Edward Abrahams (Personalized Medicine Coalition, Washington, United States)
17:10 - 17:20
Current and Future Key Initiatives in Personalized Medicine in Europe
Angela Brand (Maastricht University, Maastricht, Netherlands)
17:20 - 17:30
Predictive, Preventive and Personalized Medicine (PPPM) as National
and International Healthcare Services of the Newest Generation
Sergey Suchkov (I.M.Sechenov First Moscow State Medical University, Moscow,
Russian Federation)
17:30 - 17:40
Implementation of Personalized Health Care Worldwide
Ansgar Hebborn (Hoffmann-La Roche, Switzerland)
17:40 - 18:00
Panel Discussion
Poster Session
An Empirical Approach to Bridge the Gap Between Hypothetical Ethics and the Current
Status of Systems Medicine Research in Germanya
Tobias Fischer (University Medicine Greifswald, Greifswald, Germany)
A Need for Global Understanding of Personalized and P4 Medicines
Chantal Bouffard (Université de Sherbrooke, Sherbrooke, Canada)
Development of a Therapy for Duchenne Muscular Dystrophy Using either TALEN or Cas9
Proteins
Daniel Agudelo (Chu de Québec/Laval University, Québec, Canada)
Exome Sequencing Multiple Pipeline Analysis in Finding Mutated Candidate Genes
Associated with Pitiutary Stalk Interruption Syndrome (PSIS)
Martineau Jean-Louis (Université de Montréal, Montreal, Canada)
Quebec Breast Cancer Foundation Tissue Microarray Consortium for Biomarker Evaluation
Veronique Ouellet (CR-CHUM/Université de Montréal, Montreal, Canada)
Page 13 / 19
The Canadian Prostate Cancer Biomarker Network (CPCBN): A Validation Cohort for Prostate
Cancer Biomarkers
Veronique Ouellet (CR-CHUM/Université de Montréal, Montreal, Canada)
Systematic Review Protocol to Evaluate the Effectiveness and Cost Effectiveness of
Personalised Surveillance after Colorectal Adenomatous Polypectomy
Ethna McFerran (Queen's University Belfast, Belfast, United Kingdom)
Biological Profiles of Patients with Inflammatory Bowel Disease Based on Genetic Risk
Factors
Alexandre Paradis (Hôpital Maisonneuve-Rosemont, Montréal, Canada)
Does Clinical Guidelines Affect Healthcare Quality and Populational Health : Quebec
Colorectal Cancer Screening Program
Nizar Ghali (Laval University, Quebec, Canada)
Surveillance in Antimicrobial Resistance and The Implementation of a Web-Based Monthly
Antibiogram Report for the Adequate Antibiotic Prescription
Christian Mendoza-Mujica (University of Guadalajara, Guadalajara, Mexico)
The Melanocortin 1 Receptor (Mc1r) and Prepro-Opiomelanocortin (Pomc) are Transcribed in
Numerous Extracutaneous Sites of the Developing Avian Embryo
Magalie Carey (L'institut national de la santé et de la recherche médicale (INSERM UMR_S910),
Marseille, France)
Noninvasive Prenatal Testing Using Cell-Free Circulating DNA: Towards the Clinical
Implementation of New Genomic Methods
Loubna Jouan (Sainte-Justine Hospital, Montreal, Canada)
COEUR: A Pan-Canadian Platform for the Development of Biomarker-Driven Subtype Specific
Management of Ovarian Carcinoma
Laudine Communal (Montréal, Canada)
Autoantibody Epitope Mapping as Diagnostic Tool for Pancreatic Ductal Adenocarcinoma
Christina Lehrer (German Cancer Research Center, Heidelberg, Germany)
CLINPRADIA 1: A Multicentre Stepped-Wedge Cluster Randomized Trial on The
Management of Microalbuminuria in Hypertensive Type 2 Diabetes
Rachel Jean-Baptiste (CRCHUM, Montreal, Canada)
Role of HCaRG/COMMD5 in Epithelial-Mesenchymal Transition during Ischemia
Thomas Verissimo (Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM),
Montréal, Canada)
Estimation of Fetal Macrosomia among the Cree in the Eastern James Bay
Elisa Jean-Baptiste (URCA-Centre de recherche du CHU Sainte-Justine, Montréal, Canada)
Clinically Actionable Pharmacogenomics from Germline DNA
Michel Cameron (BiogeniQ, Montreal, Canada)
Trends in the Clinical Development of Cellular Immunotherapies and Implications for
Emerging Business Models
Katherine Bonter (PCITP, Hopital Maisoneuve Rosemont, Montreal, Canada)
Page 14 / 19
Development of a Pharmacoeconomic Model to Assess the Cost-Effectiveness of
Pharmacogenomics (PGx) Tests In Chronic Heart Failure: The Case of Ivabradine
Ange Christelle Iliza (Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montréal,
Canada)
CellCAN: Moving Regenerative Medicine and Cell Therapy forward
Denis Claude Roy (Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Canada)
What Pregnant Women Think about Prenatal Testing and their Responsibility in the Context
of Prenatal Personalized Medicine
Gabrielle Lapointe (Université de Sherbrooke, Sherbrooke, Canada)
Health Care Providers´ Payment with Personalized Medicine
Samuel Kembou Nzale (Aix-Marseille School of Economics (CNRS, EHESS), Marseille, France)
HCaRG,
Injury
A New Potential EGFR-Targeted Therapy to Improve Tissue Repair after Renal
Carole Campion (CR-CHUM, Montreal, Canada)
Genetic Risk Score of Clinical Biomarkers and Cardiovascular Risk Prediction in Patients
with Type-2 Diabetes: Data from The ADVANCE Trial
Muhammad Ramzan Tahir (CRCHUM, Montreal, Canada)
Integrating Multi-Omics Discovery Approaches to Identify Biomarkers of Therapeutic
Resistance in Metastatic Colorectal Cancer Patients through Analyses of Sequential Tumor
and Liquid Biopsies; Q-CROC-01: NCT00984048
Karen Gambaro (Quebec Clinical Research Organization in Cancer, Montreal, Canada)
Merging Pharmacogenomic and Phenomic Data for Patient Drug Metabolism Efficacy by
Help Decision Making System
Candan Hızel (Pharmacogenomics Research Centre-BIFAGEM, Izmir, Turkey)
Genetic Risk Score of Age of Onset of Diabetes Adapted to Ancestral origin Predicts Early
Death
Francois Harvey (CRCHUM, Montreal, Canada)
International Overview of Policies Options to Address Genetic Discrimination in the Fields of
Insurance and Employment
Lingqiao Song (McGill University, Montreal, Canada)
The Principle of Mutual Recognition and Research Ethics Review in the Era of Personalized
Medicine: A Model Policy?
Vasiliki Rahimzadeh (McGill University, Montreal, Canada)
Epigenomics ELSI: The Research of the International Human Epigenome Consortium
Bioethics Workgroup
Stephanie Dyke (McGill University, Montreal, Canada)
Whiter Gatekeepers and Trusted Third Parties?
Gratien Dalpé (CGP McGill University, Montreal, Canada)
ELSI Tools for the Genomic Cloud
Mark Phillips (Centre of Genomics and Policy, McGill University, Montreal, Canada)
Page 15 / 19
Cognitive Computing in Precision Medicine
Aditya Pai (IBM Watson Health, Toronto, Canada)
Personalized Therapy Targeted Genetic Mutations Associated with Metastatic Clear Cell
Renal Cell Carcinoma
John Zhong (University of Southern California, Los Angeles, United States)
A Novel Laser-Assisted Microarray Technology for Antibody Readout of the Humoral Immune
Response
Felix F. Loeffler (Karlsruhe Institute of Technology, Eggenstein-Leopoldshafen, Germany)
Association between Irinotecan Toxicity and Genetic polymorphisms of Drug Metabolic
Enzymes in Turkish Cancer Patients
Duygu Abbasoğlu (Anadolu University,, Eskişehir, Turkey)
Page 16 / 19
Wednesday, 15 June 2016
08:30 - 09:30
P3
Public-Private Partnership and Interdisciplinarity as Pillars
of Patient-Centric Innovations
Chair: Martin Godbout (Génome Québec, Montreal, Canada)
08:30 - 09:30
Public-Private Partnership and Interdisciplinarity as Pillars of PatientCentric Innovation
Michel Goldman (Université libre de Bruxelles, Brussels, Belgium)
09:30 - 10:00
Coffee Break
Panel, 517 D
10:00 - 11:45
P4
Interdisciplinarity in Personalized Health Care
Chair: Michel Goldman (Université libre de Bruxelles, Brussels, Belgium)
10:00 - 10:20
Benefiting from Foreign Knowledges: How and Why Personalized
Medicine Produces Patient Compliance
Violaine Lemay (Université de Montreal, Montreal, Canada)
10:20 - 10:40
Consenting via a Screen: Unlocking the ELSI of “mHealth Research” in
Canada
Amy Pack (McGill University, Montreal, Canada)
10:40 - 11:00
Integrating the Patient Perspective in an Era of Precision Medicine
Carmen Loiselle (McGill University, Montreal, Canada)
11:00 - 11:20
Bringing Patient Advisors to the Bedside of Digit Replantation Patients: A
Promising Personalized Care Model for Improving the Perception of
Disability and the Rehabilitation Process
Johanne Higgins (School of Rehabilitation, Faculty of Medicine, Université de
Montréal, Montreal, Canada)
Page 17 / 19
Session, 524 ABC
10:00 - 11:45
CS11
Réseau de médecine génétique appliquée (RMGA) /
Network of Applied Genetic Medicine
The Session will highlight each of the RMGA’s five Strategic Themes, with
particular regard toward personalized health care. The Session will be comprised
of a short (10 min) introduction to the RMGA, followed by five longer (15 min)
sessions, each describing the platforms and activities of each Strategic Theme: 1)
Patient Registries and Biobanks; 2) Population and Statistical Genetics; 3) Nextgeneration Integrative Genomics; 4) Health Technology Transfer; and 5) Legal and
socio-ethical issues. Each session will be presented by one of the representatives
of each Strategic Theme. There will be a few minutes at the end of each
presentation for audience questions.
Chair: Ronald Lafreniere (CHU Ste Justine, Montreal, Canada)
10:00 - 10:20
Population and Statistical Genetics
Simon Gravel (Canada)
10:20 - 10:40
Patient Registries and Biobanks
Jack Puymirat (Canada)
10:40 - 11:00
Integrative Genomics
Tomi Pastinen (Canada)
11:00 - 11:20
Legal and Socio-ethical Issues
Yann Joly (McGill University, Montreal, Canada)
11:20 - 11:40
Health Technology Transfer
Session, 519 AB
10:00 - 11:45
10:00 - 10:20
LSARP3
Data Exchange and Systems (presented by Genome
Canada and CIHR)
PEGASUS: PErsonalized Genomics for prenatal Aneuploidy Screening
USing maternal blood PÉGASE: PErsonalisation par la Génomique du
dépistage des Aneuploïdies dans le Sang matErnel
10:20 - 10:40
Parent Perspectives on Whole Genome Sequencing for Autism Spectrum
Disorder
Michael Szego (The Hospital for Sick Children, Toronto, Canada)
10:40 - 11:00
The Host-gut Microbiota Dialogue: A Gateway for Personalized Health
Alain Stintzi (University of Ottawa, Ottawa, Canada)
11:00 - 11:20
Personalized medicine strategies for molecular diagnostics and targeted
therapeutics of cardiovascular diseases
Jean-Claude Tardif (Montreal Heart Institute, Canada)
Page 18 / 19
12:00 - 13:00
Closing Ceremony
12:00 - 12:45
Where Do We Go from Here in Personalizing Health Care?
Pavel Hamet (CHUM, Montreal, Canada)
Page 19 / 19
Powered by TCPDF (www.tcpdf.org)

Scientific Programme Sunday, 12 June 2016 16:00

Transcription

Documents pareils

Guide de l`exposant - Salon Véhicule Électrique Montréal

centre eaton montréal - Neo

Holiday Inn Montreal Aéroport-Airport est heureux de

offre d`emploi agente de correction du langage

Ville de Montréal - Inspecteur des aliments

SOCIÉTÉ DES ALCOOLS DU QUÉBEC Construction forfaitaire

http://ville.montreal.qc.ca/emploi

Réponse additionnelle de Viger DMC International à la question de

Les 100 ans du Centre de sante du Y des femmes de Montreal

Bonne nouvelle! Great news!